Genentech, Inc. has announced that the U.S. Food and Drug Administration (FDA) approved Lucentis® (ranibizumab injection) 0.3 mg for the monthly treatment of all forms of diabetic retinopathy. The most common cause of vision loss in people with diabetes, diabetic retinopathy is the leading cause of blindness among adults aged 20 to 74 and affects [Read More]
News
New Sustained Delivery Method for Lucentis
Genentech, Inc. is testing a less-invasive method of delivery of their anti-VEGF drug Lucentis into the eyes of patients with wet AMD. Currently, anti-VEGF treatments require regular monthly or bi-monthly injections into the back of the eye, which can be taxing on patients’ time and stress level. The new method utilizes a timed release capsule [Read More]
Brain "rewires" itself to enhance other senses in blind people
A common belief that blind people possess unusually heightened non-visual senses now may be more than just a belief. A new study led by Massachusetts Eye and Ear researchers has found that the brains of those who are born blind make new connections in the absence of visual information. This results in heightened senses of hearing, [Read More]
Assistive Technology in the Middle Lane
by Dan Roberts When it comes to assistive technology for the blind and visually impaired, so many options present themselves that it may be helpful to visualize them on a three-lane highway. Devices in the slow lane are basic low-tech optical and non-optical aids. Devices in the middle lane use electronics and digital technology to [Read More]
Once-Promising Study of Encapsulated Cell Technology Halted
Researchers have found no significant difference between patients implanted with capsules manufacturing the drug NT-503 and patients receiving anti-VEGF drug injections. As reported on this site in 2015, Neurotech Pharmaceuticals, Inc. announced a Phase 2 clinical study of NT-503 Encapsulated Cell Therapy (ECT) for the treatment of wet age-related macular degeneration (AMD). The study planned [Read More]